tbuckley/cabot-search huggingface dataset:
Gene Transfer of CD40-Ligand to Human Dendritic Cells Induces Growth Arrest and Apoptosis of Tumor Cells Mediated by Up-Regulated TRAIL and its Receptors.
Authors: Kei Tomihara, Kazunori Kato, Yukari Masuta, Makoto Noguchi, Hiroyoshi Hiratsuka, Hirofumi Hamada
Journal: Blood (2004)
Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)
Authors: Alyssa I. Clay, Theresa Hahn, Leah Preus, Kenan Onel, Qianqian Zhu, Christopher Haiman, Daniel O. Stram, Loreall C. Pooler, Xin Sheng, Daniel Weisdorf, Li Yan, Qian Liu, Qiang Hu, Song Liu, Sebastiano Battaglia, Xiaochun Zhu, AnneMarie W. Block, Sheila Sait, Christine B. Ambrosone, David Tritchler, Stephen R. Spellman, Marcelo C. Pasquini, Philip L. McCarthy, Lara E. Sucheston-Campbell
Journal: Blood (2015)
Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies,
Authors: Stefanie Koristka, Marc Cartellieri, Anke Theil, Claudia Arndt, Anja Feldmann, Irene Michalk, Marc Schmitz, Karsten Kretschmer, Martin Bornhäuser, Gerhard Ehninger, Michael Bachmann
Journal: Blood (2011)
Migratory and Dancing Macrophage Subsets in Atherosclerotic Lesions
Authors: Sara McArdle, Konrad Buscher, Yanal Ghosheh, Akula Bala Pramod, Jacqueline Miller, Holger Winkels, Dennis Wolf, Klaus Ley
Journal: Circulation Research (2019)

Rationale: Macrophages are essential regulators of atherosclerosis. They secrete cytokines, process lipoproteins and cholesterol, and take up apoptotic cells. Multiple subsets of plaque macrophages exist and their differential roles are emerging. Objective: Here, we explore macrophage heterogeneity in atherosclerosis plaques using transgenic fluorescent mice in which subsets of macrophages are labeled by GFP (green fluorescent protein), YFP (yellow fluorescent protein), neither, or both. The objective was to define migration patterns of the visible subsets and relate them to their phenotypes and transcriptomes. Methods and Results: Apoe −/− Cx3cr1 GFP Cd11c YFP mice have 4 groups of macrophages in their aortas. The 3 visible subsets show varying movement characteristics. GFP and GFP+YFP+ macrophages extend and retract dendritic processes, dancing on the spot with little net movement while YFP macrophages have a more rounded shape and migrate along the arteries. RNA sequencing of sorted cells revealed significant differences in the gene expression patterns of the 4 subsets defined by GFP and YFP expression, especially concerning chemokine and cytokine expression, matrix remodeling, and cell shape dynamics. Gene set enrichment analysis showed that GFP+ cells have similar transcriptomes to cells found in arteries with tertiary lymphoid organs and regressing plaques while YFP+ cells were associated with progressing and stable plaques. Conclusions: The combination of quantitative intravital imaging with deep transcriptomes identified 4 subsets of vascular macrophages in atherosclerosis that have unique transcriptomic profiles. Our data link vascular macrophage transcriptomes to their in vivo migratory function. Future work on the functional significance of the change in gene expression and motility characteristics will be needed to fully understand how these subsets contribute to disease progression.
An Unusual Case of ‘Delayed‘ Febrile Non Hemolytic Transfusion Reaction in a Thalassemia Major Patient with Asymptomatic Plasmodium Falciparum Infection.
Authors: Carla Boschetti, Franca Radaelli, Mariangela Colombi, Cristina Vercellati, Luisa Caspani, Romualdo Grande, Maria Domenica Cappellini, Alberto Zanella
Journal: Blood (2009)
Intensified Chemotherapy Regimen for Very High Risk Childhood B-Precursor Acute Lymphoblastic Leukemia (B-ALL): Results From Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05–01
Authors: Lynda M. Vrooman, Kristen E. Stevenson, Marian Harris, Donna S. Neuberg, Stephen E. Sallan, Lewis B. Silverman
Journal: Blood (2012)
CRISPR/Cas9 gene editing of brain cancer stem cells using lipid-based nano-delivery
Authors: Nadia Rouatbi, Yau Mun Lim, Vivien Grant, Pedro Miguel Costa, Steven M Pollard, Julie Tzu-Wen Wang, Khuloud T Al-Jamal
Journal: Neuro-Oncology (2019)

Abstract Despite advances in cancer therapy glioblastoma (GBM) remains one of the deadliest brain tumours. Effective therapy is restricted by the presence of multiple resistance mechanisms. Physical barriers such as the blood-brain barrier limit the brain delivery of therapeutic compounds. In addition, the presence of a subset of GBM-stem-like cells (GSCs), characterized by radio/chemoresistance, and the intratumor heterogeneity impede standard therapies from being effective. New therapeutic approaches are urgently needed. Given its high specificity, CRISPR/Cas9-mediated genome editing provides new prospects for novel therapeutic targets. While promising, in vivo application of CRISPR/Cas9 is currently hampered by poor pharmacokinetics and limited ability to cross biological membranes. The present research is designed to utilise stable nucleic acid lipid nanoparticles (SNALPs) for in vivo delivery of CRISPR/Cas9 to GSC by disrupting the epidermal growth factor receptor variant III (EGFRvIII), a GBM associated mutation, responsible for tumour cell proliferation, angiogenesis and invasion. Near Infrared fluorescence labelling and live optical imaging confirmed SNALPs uptake in GSC tumours implanted intracranially in mice after intravenous injection. Higher uptake of SNALPs in tumourous tissues compared to healthy brain tissues was further confirmed by ex vivo imaging and flow cytometry. EGFRvIII-specific sgRNA has been designed and validated in GSCs using commercial transfection regents. Studies are underway to load CRISPR/Cas9 mRNA/gRNA into SNALPs to test their in vitro gene editing efficacy. Successful in vivo delivery of CRISPR/Cas9 will represent a promising approach for identifying GBM therapeutic targets in vivo which in the long-run can be applied for GBM treatment.
Prognostic Significances of ABCG-2 and hOCT-1 Gene Expression in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.
Authors: Yeo-Kyeoung Kim, Hee-Nam Kim, Jae-Sook Ahn, Deok-Hwan Yang, Il-Kwon Lee, Je-Jung Lee, Hyeoung-Joon Kim
Journal: Blood (2009)
Novel Mouse Models of Chronic Lymphocytic Leukemia (CLL) Unravel the Molecular Mechanisms Controlling Bone Marrow Involvement by Leukemic B Cells.
Authors: Paolo Ghia, Maria TS Bertilaccio, Cristina Scielzo, Giorgia Simonetti, Benedetta Apollonio, Claudia Fazi, Marta Muzio, Maurilio Ponzoni, Federico Caligaris-Cappio
Journal: Blood (2009)
It is time to move beyond ‘body region silos’ to manage musculoskeletal pain: five actions to change clinical practice
Authors: J P Caneiro, Ewa M Roos, Christian J Barton, Kieran O'Sullivan, Peter Kent, Ivan Lin, Peter Choong, Kay M Crossley, Jan Hartvigsen, Anne Julia Smith, Peter O'Sullivan
Journal: British Journal of Sports Medicine (2019)

Current clinical research, education and practice commonly approaches musculoskeletal pain conditions in silos. A focus on body regions such as knee, hip, neck, shoulder and back pain as separate entities is manifest by region-specific clinical guidelines, conferences and working groups. Emerging evidence demonstrates that musculoskeletal pain disorders are frequently comorbid and share common biopsychosocial risk profiles for pain and disability.1–5 There is broad consensus across clinical guidelines on the recommendations for best practice, irrespective of body region.3 We contend that a shift to focus on the person is needed. This best practice approach will encourage clinicians to (1) focus on patients’ context and modifiable biopsychosocial factors that influence their pain and disability3; (2) use education to facilitate active management approaches (targeted exercise therapy, physical activity and healthy lifestyle habits) and reduce reliance on passive interventions; and (3) consider evidence-based surgical procedures only for those with a clear indication and where guideline-based non-surgical approaches have been rigorously adhered to.

To adopt a person-centred active approach to treating musculoskeletal pain and disability, clinicians should:

### 1. Screen for biopsychosocial factors and health comorbidities

Clinicians need to communicate clearly with the patient to identify potential biopsychosocial drivers of …
3 cases of undifferentiated embryonal sarcoma of the liver (UESL) in adult
Authors: Motoko Arakaki, Kazuki Sudo, Yuki Kojima, Yohei Ohtake, Takuji Seo, Hitomi Okuma, Emi Noguchi, Maki Tanioka, Akihiko Shimomura, Kan Yonemori, Akihiko Yoshida, Yasuhiro Fujiwara, Kenji Tamura
Journal: Annals of Oncology (2019)
Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography
Authors: Jin Li, Konstantinos Zormpas-Petridis, Jessica K.R. Boult, Emma L. Reeves, Andreas Heindl, Maria Vinci, Filipa Lopes, Craig Cummings, Caroline J. Springer, Louis Chesler, Chris Jones, Jeffrey C. Bamber, Yinyin Yuan, Ralph Sinkus, Yann Jamin, Simon P. Robinson
Journal: Cancer Research (2019)

Increased stiffness in the extracellular matrix (ECM) contributes to tumor progression and metastasis. Therefore, stromal modulating therapies and accompanying biomarkers are being developed to target ECM stiffness. Magnetic resonance (MR) elastography can noninvasively and quantitatively map the viscoelastic properties of tumors
Cross-Species Comparison of Acquired Genetic Changes In T Cell Malignancy.
Authors: Lynnie A. Rudner, Kim H. Brown, Kimberly P. Dobrinski, Diana F. Bradley, Jonathan Downie, Nathan D. Meeker, Alexandra Smith, Martha Iveth Garcia, Alejandro Gutierrez, Charles Mullighan, A. Thomas Look, James R. Downing, Joshua D. Schiffman, Charles Lee, Nikolaus Trede, J. Kimble Frazer
Journal: Blood (2010)
Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo
Authors: Mariko Sato, Kota Fujimori, Shotaro Kitabatake, Mikio Okayama, Daiju Ichikawa, Yutaka Suto, Genji Iwasaki, Fumiyuki Kiuchi, Takashi Yamaguchi, Arimi Ueda, Shuji Aida, Hitomi Nakayama, Maiko Matsushita, Yutaka Hattori
Journal: Blood (2016)
High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells
Authors: Jueqiong WANG, Chung Hoow Kok, Tamara M Leclercq, Verity A Saunders, Richard J D'Andrea, Timothy P. Hughes, Deborah L White
Journal: Blood (2015)
Transfer and Metabolism of the Xenoestrogen Zearalenone in Human Perfused Placenta
Authors: Benedikt Warth, Karin Preindl, Pius Manser, Peter Wick, Doris Marko, Tina Buerki-Thurnherr
Journal: Environmental Health Perspectives (2019)

Pregnancy is a sensitive condition during which adverse environmental exposures should be monitored thoroughly and minimized whenever possible. In particular, the hormone balance during gestation is delicate, and disturbance may cause acute or chronic long-term health effects. A potential endocrine disruption may be provoked by in utero exposure to xenoestrogens mimicking endogenous estrogens. The mycoestrogen zearalenone (ZEN), a toxic fungal secondary metabolite and mycotoxin found frequently in food and feed, constitutes a prominent example.We performed a comprehensive assessment of the transfer as well as phase I and phase II metabolism of ZEN at the human placental barrier.Human placentas were perfused with 1μM (318μg/L) ZEN for 6 h. Samples from the maternal and fetal compartment, placental tissue, and fetal plasma were analyzed by a highly sensitive UHPLC-MS/MS assay to detect ZEN as well as nine key metabolites (α-zearalenol, β-zearalenol, zearalanone, α-zearalanol, β-zearalanol, ZEN-14-glucuronide, α-zearalenol-14-glucuronide, β-zearalenol-14-glucuronide, ZEN-14-sulfate).The model revealed a fast maternofetal transfer of ZEN across the human placental barrier. We also unraveled phase I and phase II metabolism of the parent toxin ZEN into the approximately 70-times more estrogenic α-zearalenol and the less active ZEN-14-sulfate conjugate, which are effectively released into the maternal and fetal circulation in considerable amounts.Our findings suggest that exposure to ZEN (such as through consumption of ZEN-contaminated cereal-based products) during pregnancy may result in in utero exposure of the fetus, not only to ZEN but also some of its highly estrogenically active metabolites. In the light of the known affinity of ZEN and potentially co-occurring xenoestrogens to the estrogen receptor, and our results demonstrating placental transfer of ZEN and its metabolites in an ex vivo model, we recommend further research and more comprehensive assessment of gestational exposures in women. https://doi.org/10.1289/EHP4860.
Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
Authors: Yi-Ling Chen, Danuta Gutowska-Owsiak, Clare S. Hardman, Melanie Westmoreland, Teena MacKenzie, Liliana Cifuentes, Dominic Waithe, Antonia Lloyd-Lavery, Allison Marquette, Marco Londei, Graham Ogg
Journal: Science Translational Medicine (2019)

First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Allogeneic Platelet MHC Class I Antigens Prevent CD61 Specific Cytotoxic T Cell (CTL)-Mediated Immune Thrombocytopenia (ITP).
Authors: Li Guo, Rukhsana Aslam, Edwin R Speck, Heyu Ni, Ming Hou, John J. Freedman, John W. Semple
Journal: Blood (2010)
Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughput Sequencing Assay
Authors: Yasuhiro Oki, Sattva S. Neelapu, Michelle A. Fanale, Larry W. Kwak, Luis E Fayad, Alma Rodriguez, Michael Wallace, Victoria Carlton, Katherine Kong, Malek Faham, Anas Younes
Journal: Blood (2013)
Autologous and Allogeneic Stem Cell Transplantation for Richter's Transformation: A Retrospective Analysis From the Chronic Leukaemia Working Party and Lymphoma Working Party of the EBMT.
Authors: Kate Cwynarski, Anja van Biezen, Ronald Brand, Marijke Scholten, Bernd Metzner, Mohamad Mohty, Vladimir Koza, Maija Itala-Remes, Fabio Ciceri, Arnon Nagler, T. M. de Witte, Anna Sureda, Peter Dreger
Journal: Blood (2009)
Symptoms of Anxiety and Depression Among Teens and Adults in the Thalassemia Longitudinal Cohort Study.
Authors: Lauren Mednick, Shuli Yu, Felicia Trachtenberg, Dorothy A. Kleinert, Patricia J Giardina, Janet L Kwiatkowski, Dru Foote, Vivekanandan Thayalasuthan, John B Porter, Alexis A. Thompson, Leann Schilling, Charles T. Quinn, Ellis J Neufeld, Robert Yamashita
Journal: Blood (2009)
Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumours (NSGCT): Final results of phase II trial
Authors: None Tryakin, M. Fedyanin, Y. Segeev, A. Bulanov, V.B. Matveev, M. Volkova, A. Klimov, I. Fainstein, B. Akhmedov, S. Menshikova, T. Zakharova, A.M. Garin, D. Chekini, A. Chekini, O. Sekhina, S. Tjulandin
Journal: Annals of Oncology (2019)
Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study
Authors: Oana A Zeleznik, Clary B Clish, Peter Kraft, Julian Avila-Pacheco, A Heather Eliassen, Shelley S Tworoger
Journal: JNCI Journal of the National Cancer Institute (2019)

Experimental evidence supports a role of lipid dysregulation in ovarian cancer progression. We estimated associations with ovarian cancer risk for circulating levels of four lipid groups, previously hypothesized to be associated with ovarian cancer, measured 3-23 years before diagnosis.Analyses were conducted among cases (N = 252) and matched controls (N = 252) from the Nurses' Health Studies. We used logistic regression adjusting for risk factors to investigate associations of lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), ceramides (CERs), and sphingomyelins (SMs) with ovarian cancer risk overall and by histotype. A modified Bonferroni approach (0.05/4 = 0.0125, four lipid groups) and the permutation-based Westfall and Young approach were used to account for testing multiple correlated hypotheses. Odds ratios (ORs; 10th-90th percentile), and 95% confidence intervals of ovarian cancer risk were estimated. All statistical tests were two-sided.SM sum was statistically significantly associated with ovarian cancer risk (OR = 1.97, 95% CI = 1.16 to 3.32; P = .01/permutation-adjusted P = .20). C16:0 SM, C18:0 SM, and C16:0 CERs were suggestively associated with risk (OR = 1.95-2.10; P = .004-.01; permutation-adjusted P = .08-.21). SM sum, C16:0 SM, and C16:0 CER had stronger odds ratios among postmenopausal women (OR = 2.16-3.22). Odds ratios were similar for serous/poorly differentiated and endometrioid/clear cell tumors, although C18:1 LPC and LPC to PC ratio were suggestively inversely associated, whereas C18:0 SM was suggestively positively associated with risk of endometrioid/clear cell tumors. No individual metabolites were associated with risk when using the permutation-based approach.Elevated levels of circulating SMs 3-23 years before diagnosis were associated with increased risk of ovarian cancer, regardless of histotype, with stronger associations among postmenopausal women. Further studies are required to validate and understand the role of lipid dysregulation in ovarian carcinogenesis.
Targeted Depletion of B-Cell Subsets by Anti-CD22 and Anti-CD79bAntibody Drug Conjugates: Illumination of the Mechanism of Action through Pharmacodynamic Biomarkers
Authors: Franklin Fuh, Caroline Looney, Dongwei Li, Kirsten Achilles Poon, Randall Dere, Vanitha Ramakrishnan, Andrew Polson, Saileta Prabhu, Marna Williams
Journal: Blood (2010)
Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies
Authors: Christian Gordillo, Sapna Parmar, Miranda Blanco, Elsa Marie Delille, Amer Assal, Markus Y Mapara, Ran Reshef
Journal: Blood (2017)
Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong
Authors: Herbert Hf Loong, Carlos Kh Wong, Chu-Wa Ho, Teresa Tse, Sui-Chun Sampson Kwan, Yat-Ming Lau, Linda Ks Leung
Journal: Annals of Oncology (2019)
Tracking Normal and Chronic Myeloid Leukemia Progenitor Cell Cycle Kinetics in a Defined Niche Using Live Time Lapse Confocal Imaging with Fucci2BL a Novel Lentiviral Bicistronic Reporter
Authors: Gabriel Pineda, Kathleen M Lennon, Nathaniel P Delos-Santos, Florence Lambert-Fliszar, Gennarina L Riso, Marco A Marra, Sheldon Morris, Asako Sakaue-Sawano, Atsushi Miyawaki, Catriona HM Jamieson
Journal: Blood (2015)
Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis
Authors: Priscilla Do, Kyle A. Beckwith, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, Jeffrey Jones, Erin K. Hertlein, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2016)
Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.
Authors: Martin A. Pule, Alexandra Rousseau, Elizabeth Kang, Takahiro Ueda, Christof von Kalle, Arthur W. Nienhuis, Helen Heslop, Elio Vanin, John F. Tisdale
Journal: Blood (2004)
Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials
Authors: Susanne Saussele, Mareike Stein, Arthur Gil, Ute Kossak-Roth, Michael Lauseker, Ulrike Proetel, Hermann Einsele, Philippe Schafhausen, Elisabeth Lange, Mathias Hänel, Karsten Spiekermann, Martin Sökler, Clemens Wendtner, Stephan Kremers, Michael Pfreundschuh, Ernst Holler, Wolf-Karsten Hofmann, Andreas Hochhaus, Martin C. Müller, Ruediger Hehlmann, Markus Pfirrmann
Journal: Blood (2015)
Very Early Dynamics of Regulatory T-Cell Chimerism Significantly Varies According to the Donor Sources: Implication for Basic Immune Pathogenesis of Engraftment Phase
Authors: Miki Iwamoto, Ken-ichi Matsuoka, Yusuke Meguri, Takeru Asano, Takanori Yoshioka, Yuriko Kishi, Makoto Nakamura, Yasuhisa Sando, Yoshinobu Maeda, Mitsune Tanimoto
Journal: Blood (2016)
Gender-Based Differences in Efficacy of Immuno-Chemotherapy for Diffuse Large B-Cell Lymphoma Revisited: A Danish Population-Based Study
Authors: Mette Dahl Bendtsen, Lasse Hjort Jakobsen, Judit Mészáros Jørgensen, Hans Erik Johnsen, Pär Lars Josefsson, Christian Bjørn Poulsen, Jørn Starklint, Gabriela Felicia Stein, Per Trøllund Pedersen, Jacob Haaber Christensen, Martin Bøgsted, Peter de Nully Brown, Tarec Christoffer El-Galaly
Journal: Blood (2017)
A New Score to Determine the Probability of Finding an HLA Identical Unrelated Donor: A Validated Efficient Time and Cost Saving Method
Authors: Valéerie Dubois, Mohamad Sobh, Stéphane Morisset, Hélène Labussière-Wallet, Marie Y. Detrait, Sylvie Rey, Isabelle Mollet, Sophie Ducastelle, Fiorenza Barraco, Youcef Chelghoum, Xavier Thomas, Franck E. Nicolini, Mauricette Michallet
Journal: Blood (2012)
Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells
Authors: Dyana T Saenz, Warren Fiskus, Taghi Manshouri, Baohua Sun, Stephanie Krieger, Simrit Parmar, Srdan Verstovsek, Kapil N. Bhalla
Journal: Blood (2015)
Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study
Authors: Ran Reshef, Selina M. Luger, Elizabeth O. Hexner, Alison W. Loren, Noelle V. Frey, Steven C. Goldstein, Sunita D. Nasta, Edward A. Stadtmauer, Jacqueline Smith, Rosemarie Mick, Daniel F. Heitjan, James A. Hoxie, Stephen G. Emerson, Robert H. Vonderheide, David L. Porter
Journal: Blood (2011)
Phase I Study of the Aurora B Kinase Inhibitor Barasertib (AZD1152) to Assess the Pharmacokinetics (PK), Metabolism and Excretion in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Authors: Mike Dennis, Michelle Davies, Stuart Oliver, Roy D'Souza, Laura Pike, Paul Stockman
Journal: Blood (2011)
The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response
Authors: Anna Rita Migliaccio, Mario Falchi, Lilian Varricchio, Fabrizio Martelli, Francesca Masiello, Manuela Marra, Orietta Picconi, Agostino Tafuri, Gabriella Girelli, Carolyn F. Whitsett
Journal: Blood (2016)
Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Authors: Jatin J. Shah, Lei Feng, Donna Weber, Sheeba K Thomas, Michael Wang, Francesco Turturro, Muzaffar H. Qazilbash, Nina Shah, Qaiser Bashir, Uday R. Popat, Elisabet E. Manasanch, Silvia C Munoz, Ashley Landry, Kathleen Mendoza, Yago Nieto, Richard E. Champlin, Robert Z. Orlowski
Journal: Blood (2015)
Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma
Authors: Marzia Cavalli, Lucia Anna De Novi, Irene Della Starza, Luca Cappelli, Vittorio Nunes, Alessandro Pulsoni, Ilaria Del Giudice, Anna Guarini, Robin Foa
Journal: Blood (2016)
Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study
Authors: Yoichi Naito, Toshihiko Doi, Tsuyoshi Takahashi, Toshihiro Kudo, Narikazu Boku, Yoshitaka Honma, Yoshito Komatsu, Hiroshi Nakatsumi, Koji Matsumoto, Takuma Onoe, Eiji Oki, Yasuo Tsuda, Masako Nakamoto, Miki Fukutani, Shogo Nomura, Akihiro Sato, Toshirou Nishida
Journal: Annals of Oncology (2019)
Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).
Authors: Stephan Stilgenbauer, Dirk Winkler, Alexander Kröber, Dirk Kienle, Michael Hallek, Manfred Hensel, Eva Lengfelder, Lorenz Trümper, Peter Dreger, Ulrich Jäger, Hartmut Döhner
Journal: Blood (2004)